Active Ingredient History
Lactobacillus bulgaricus is the main bacterium used for the production of yogurt. It also plays a crucial role in the ripening of some cheeses, as well as in other processes involving naturally fermented products. It is defined as homofermentive lactic acid bacteria due to lactic acid being the single end product of its carbohydrate digestion. It is also considered a probiotic. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Injuries (Phase 2/Phase 3)
Abdominal Pain (Phase 2/Phase 3)
Acute-On-Chronic Liver Failure (Phase 2/Phase 3)
Adenomatous Polyposis Coli (Phase 2)
Angina, Stable (Phase 4)
Antibiotic Prophylaxis (Phase 2)
Anti-Infective Agents (Phase 4)
Ascites (Phase 2)
Asthma (Phase 3)
Attention (Early Phase 1)
Attention Deficit Disorder with Hyperactivity (Early Phase 1)
Binge Drinking (Phase 2)
Chronic Periodontitis (Phase 3)
Clostridioides difficile (Phase 2)
Colitis, Ulcerative (Phase 4)
Communicable Diseases (Phase 4)
Crohn Disease (Phase 4)
Defecation (Phase 2/Phase 3)
Deglutition Disorders (Early Phase 1)
Dental Caries (Phase 2/Phase 3)
Dermatology (Phase 1)
Diarrhea (Phase 4)
Diverticular Diseases (Phase 3)
Drug Resistance, Bacterial (Phase 2)
Dyspepsia (Phase 2/Phase 3)
Eczema (Phase 2)
Enterocolitis, Necrotizing (Phase 3)
Fatty Liver (Phase 1)
Gastroenteritis (Phase 4)
Gastrointestinal Diseases (Phase 3)
General Surgery (Phase 2/Phase 3)
Helicobacter (Phase 2/Phase 3)
Hepatic Encephalopathy (Phase 3)
Hirschsprung Disease (Phase 2)
Hypertension, Portal (Phase 1/Phase 2)
Impulsive Behavior (Early Phase 1)
Infant, Premature (Early Phase 1)
Infections (Phase 4)
Inflammatory Bowel Diseases (Phase 3)
Interleukin-17 (Phase 1/Phase 2)
Intestinal Neoplasms (Phase 2/Phase 3)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Phase 2)
Klebsiella pneumoniae (Phase 1/Phase 2)
Liver Cirrhosis (Phase 2/Phase 3)
Metabolomics (Early Phase 1)
Mucositis (Phase 4)
Myocardium (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 1/Phase 2)
Osteoporosis (Phase 2)
Peri-Implantitis (Phase 4)
Peritonitis (Phase 2/Phase 3)
Pharmacologic Actions (Phase 4)
Probiotics (Phase 4)
Respiratory Tract Infections (Phase 3)
Rhinitis, Allergic (Phase 2)
Therapeutic Uses (Phase 4)
Urinary Tract Infections (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
